文献速递心脑血管急症

ST段抬高型心肌梗死 outcomes 的性别差异:治疗策略与年龄的效应修饰

Sex Differences in Outcomes After STEMI: Effect Modification by Treatment Strategy and Age.
PubMed 文献 · JAMA Intern Med · 2018-01-01
一句话结论在当代直接PCI时代,年轻(<60岁)女性STEMI患者30天死亡风险仍高于同龄男性(OR 1.88),该差异随年龄增长而消失。

该研究基于ISACS-TC注册研究(2010年1月至2016年1月,41家医院,8834例STEMI患者),比较女性和男性30天死亡率。女性30天死亡率显著高于男性(11.6% vs 6.0%,P<.001),但仅限于直接PCI亚组时差距缩小(7.1% vs 3.3%,P<.001)。多因素校正后,<60岁女性早期死亡风险仍高于同龄男性(OR 1.88;95%CI 1.04-3.26;P=.02),而60-74岁及>75岁组无显著差异。结论提示年轻女性STEMI患者风险更高,需关注。

要点

  • 总体STEMI患者30天死亡率女性11.6% vs 男性6.0%(P<.001),女性更高。
  • 直接PCI亚组中女性30天死亡率7.1% vs 男性3.3%(P<.001),差距缩小但仍存在。
  • 多因素校正后,<60岁女性30天死亡风险高于同龄男性(OR 1.88;95%CI 1.04-3.26;P=.02)
  • 60-74岁女性与男性风险无显著差异(OR 1.28;95%CI 0.88-1.88;P=.19)
  • >75岁女性与男性风险无显著差异(OR 1.17;95%CI 0.80-1.73;P=.40)

适用人群与场景

  • 2010年1月至2016年1月在41家医院因STEMI住院并接受药物治疗的患者,数据提交至ISACS-TC注册研究(NCT01218776)。
  • 纳入女性2657例(平均年龄66.1岁,SD 11.6)和男性6177例(平均年龄59.9岁,SD 11.7)。

研究设计与关键结果

  • 研究类型为注册研究(ISACS-TC),纳入8834例STEMI患者,来自41家医院。
  • 主要终点30天死亡率:女性11.6% vs 男性6.0%(P<.001)。
  • 直接PCI亚组30天死亡率:女性7.1% vs 男性3.3%(P<.001)。
  • 多因素校正后,<60岁女性30天死亡风险高于同龄男性(OR 1.88;95%CI 1.04-3.26;P=.02);60-74岁组OR 1.28(95%CI 0.88-1.88;P=.19);>75岁组OR 1.17(95%CI 0.80-1.73;P=.40)。
  • IPTW校正后,<60岁组OR 1.56(95%CI 1.05-2.3);60-74岁组OR 1.49(95%CI 1.15-1.92);>75岁组OR 1.21(95%CI 0.93-1.57)。

证据类型、等级与局限

  • 证据类型:注册研究(ISACS-TC)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,年轻女性STEMI患者即使在校正药物、直接PCI和其他共存疾病后,30天死亡率仍高于同龄男性,应关注该人群。
  • 作者指出,这种性别差异在60岁后下降,在老年女性中不再观察到。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Previous works have shown that women hospitalized with ST-segment elevation myocardial infarction (STEMI) have higher short-term mortality rates than men. However, it is unclear if these differences persist among patients undergoing contemporary primary percutaneous coronary intervention (PCI).

OBJECTIVE: To investigate whether the risk of 30-day mortality after STEMI is higher in women than men and, if so, to assess the role of age, medications, and primary PCI in this excess of risk.

DESIGN, SETTING, AND PARTICIPANTS: From January 2010 to January 2016, a total of 8834 patients were hospitalized and received medical treatment for STEMI in 41 hospitals referring data to the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) registry (NCT01218776).

EXPOSURES: Demographics, baseline characteristics, clinical profile, and pharmacological treatment within 24 hours and primary PCI.

MAIN OUTCOMES AND MEASURES: Adjusted 30-day mortality rates estimated using inverse probability of treatment weighted (IPTW) logistic regression models.

RESULTS: There were 2657 women with a mean (SD) age of 66.1 (11.6) years and 6177 men with a mean (SD) age of 59.9 (11.7) years included in the study. Thirty-day mortality was significantly higher for women than for men (11.6% vs 6.0%, P < .001). The gap in sex-specific mortality narrowed if restricting the analysis to men and women undergoing primary PCI (7.1% vs 3.3%, P < .001). After multivariable adjustment for comorbidities and treatment covariates, women under 60 had higher early mortality risk than men of the same age category (OR, 1.88; 95% CI, 1.04-3.26; P = .02). The risk in the subgroups aged 60 to 74 years and over 75 years was not significantly different between sexes (OR, 1.28; 95% CI, 0.88-1.88; P = .19 and OR, 1.17; 95% CI, 0.80-1.73; P = .40; respectively). After IPTW adjustment for baseline clinical covariates, the relationship among sex, age category, and 30-day mortality was similar (OR, 1.56 [95% CI, 1.05-2.3]; OR, 1.49 [95% CI, 1.15-1.92]; and OR, 1.21 [95% CI, 0.93-1.57]; respectively).

CONCLUSIONS AND RELEVANCE: Younger age was associated with higher 30-day mortality rates in women with STEMI even after adjustment for medications, primary PCI, and other coexisting comorbidities. This difference declines after age 60 and is no longer observed in oldest women.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Cenko E, Yoon J, Kedev S, et al. Sex Differences in Outcomes After STEMI: Effect Modification by Treatment Strategy and Age. JAMA Intern Med. 2018. PMID: 29630703. doi:10.1001/jamainternmed.2018.0514

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。